Aqueous Injection Manufacturing
Aqueous injections provide a practical liquid dosage form for oligonucleotide therapeutics with suitable solubility and stability profiles. Their development requires optimized formulation conditions and well-controlled manufacturing processes to maintain oligonucleotide integrity, product quality, sterility, and stability throughout the drug product lifecycle.
Protheragen offers integrated aqueous injection manufacturing services, including formulation optimization, process development, sterile filtration, aseptic manufacturing, fill-finish, quality testing, and stability studies. These capabilities support the development and manufacturing of high-quality oligonucleotide injectable products from early-stage development to clinical supply and scale-up.
Overview of Aqueous Injection Manufacturing
Aqueous injection manufacturing involves the preparation and production of sterile liquid drug products in which the active pharmaceutical ingredient is dissolved or uniformly dispersed in an aqueous formulation. For oligonucleotide therapeutics, aqueous injections can provide a convenient dosage form when the drug substance has suitable aqueous solubility, stability, and compatibility with the intended route of administration.
The development and manufacture of aqueous oligonucleotide injections require careful control of formulation and processing conditions. Key considerations include buffer composition, pH, ionic strength, osmolality, drug concentration, excipient compatibility, and protection of the oligonucleotide from chemical or physical degradation. Manufacturing operations such as solution preparation, mixing, bulk holding, sterile filtration, aseptic filling, and container closure can also influence product quality.
A well-controlled aqueous injection manufacturing process is designed to maintain the identity, purity, concentration, potency, sterility, and stability of the oligonucleotide drug product throughout manufacturing and storage. Appropriate analytical testing and stability studies are therefore important for evaluating product quality and establishing suitable manufacturing and storage conditions.
Fig.1 Terminal sterilization development paradigm for aqueous oligonucleotide products. (DeCollibus DP, et al., 2023)
Our Services
RNA drug substance manufacturing integrates RNA synthesis, downstream processing, purification, concentration, analytical testing, and quality control into a controlled production workflow. Key services focus on RNA integrity, impurity clearance, process consistency, scalability, and drug substance quality.
Aqueous Formulation Development
Protheragen develops aqueous formulations based on the physicochemical and stability characteristics of individual oligonucleotide molecules. Buffer systems, pH, ionic strength, tonicity, stabilizers, and other formulation components can be evaluated to establish a stable and manufacturable injectable formulation.
Excipient & Buffer Optimization
Appropriate excipients and buffer systems can improve oligonucleotide stability and product performance. Protheragen evaluates formulation components and their concentrations to balance stability, compatibility, tolerability, and manufacturing feasibility.
Formulation & Process Compatibility
The selected formulation is evaluated against critical manufacturing operations to identify potential interactions or product quality changes during compounding, mixing, filtration, transfer, filling, and storage. This helps ensure that formulation performance is maintained throughout the manufacturing process.
Manufacturing Process Development
Protheragen develops controlled manufacturing processes for aqueous oligonucleotide injections, including solution preparation, compounding, mixing, bulk handling, filtration, and filling. Critical process parameters are evaluated to support reproducible drug product manufacturing.
Sterile Filtration & Aseptic Manufacturing
For suitable aqueous formulations, Protheragen supports sterile filtration and aseptic manufacturing strategies. Filtration conditions, membrane compatibility, product recovery, and process controls are assessed to support sterile and consistent drug product production.
Aseptic Filling & Finish
Protheragen provides aseptic filling and finishing of aqueous oligonucleotide drug products into suitable primary containers. Filling volume, container closure systems, handling conditions, and packaging configurations can be optimized according to product and development requirements.
In-Process & Finished-Product Testing
Manufacturing batches are supported by appropriate in-process controls and finished-product testing. Depending on product requirements, testing may include appearance, pH, osmolality, concentration, purity, potency, particulate matter, sterility, endotoxin, and other relevant quality attributes.
Stability & Storage Studies
Protheragen integrates stability evaluation into aqueous injection development to assess product performance during storage. Long-term, accelerated, photostability, and other relevant studies can be designed according to development stage and product characteristics.
Formulation Considerations for Oligonucleotide Aqueous Injections
The formulation of an aqueous oligonucleotide injection requires careful evaluation of molecular properties, formulation composition, and product performance. Key considerations include:
Drug Substance Solubility
Oligonucleotide solubility directly affects the feasible drug concentration and formulation design. Solubility should be evaluated across relevant pH, ionic strength, and excipient conditions to establish an appropriate concentration range for the intended dosage.
pH & Buffer System
pH and buffer composition can influence oligonucleotide stability, solubility, degradation, and compatibility with other formulation components. An appropriate buffer system and pH range are therefore important for maintaining product quality during manufacturing and storage.
Ionic Strength & Osmolality
Ionic strength can affect molecular interactions and the physical behavior of oligonucleotide formulations. Osmolality is also an important consideration for injectable products and should be controlled within an appropriate range for the intended administration route.
Excipient Compatibility
Excipients such as stabilizers, tonicity modifiers, surfactants, and other formulation components may be evaluated to improve product stability and performance. Their compatibility with the oligonucleotide and other formulation ingredients should be carefully assessed.
Concentration & Physical Stability
Drug concentration can influence solubility, aggregation, viscosity, adsorption, and overall formulation stability. The target concentration should therefore be established by balancing dose requirements, product stability, and manufacturing feasibility.
Container Closure Compatibility
The interaction between the aqueous formulation and its primary container or closure system can affect product quality during storage. Potential adsorption, material compatibility, and container closure performance should be evaluated to help maintain product integrity throughout the intended shelf life.
Analytical & Quality Control Support
Aqueous injection manufacturing is supported by analytical methods capable of monitoring both the oligonucleotide and the finished drug product.
Protheragen can integrate analytical development and quality research into the manufacturing program, supporting:
- Identity testing
- Assay and concentration determination
- Purity and impurity profiling
- Related-substance analysis
- Degradation product monitoring
- pH and osmolality testing
- Potency or activity testing
- Particulate matter testing
- Sterility testing
- Bacterial endotoxin testing
- Container closure integrity assessment
- Stability-indicating analytical testing
Where necessary, analytical methods can be developed, optimized, validated, or transferred according to project stage and testing requirements.
Stability Support for Aqueous Injections
Stability is a critical consideration for aqueous oligonucleotide drug products because the formulation must maintain acceptable quality throughout manufacturing, storage, transportation, and use.
Protheragen can support stability programs covering:
Long-term studies are used to monitor product quality under the proposed storage conditions and support shelf-life assessment.
Accelerated studies provide an efficient approach for evaluating formulation behavior and identifying potential degradation pathways during development.
Where relevant, photostability studies can assess the sensitivity of the aqueous formulation to light exposure.
Forced degradation studies can help identify degradation pathways and generate information required for stability-indicating analytical methods.
For products requiring preparation, handling, or administration over a defined period, in-use stability studies can evaluate product quality under representative conditions.
Why Choose Protheragen
- Integrated Development & Manufacturing
Protheragen combines formulation development, process development, analytical support, stability research, and drug product manufacturing within an integrated service platform.
- Oligonucleotide-Focused Expertise
Manufacturing strategies are developed with consideration of the unique physicochemical and stability characteristics of oligonucleotide therapeutics.
- Flexible Development Support
Services can be tailored to different development stages, from early formulation screening and preclinical batches to clinical-stage manufacturing and process scale-up.
- Quality-Focused Manufacturing
Critical quality attributes and process parameters are evaluated throughout development to support consistent and reproducible drug product quality.
- Scalable Manufacturing Strategy
Processes are designed with future scale-up and technology transfer considerations in mind, helping facilitate progression from development batches toward larger-scale manufacturing.
- Integrated Analytical & Stability Support
Analytical characterization and stability research can be coordinated with manufacturing activities to provide a more complete understanding of product quality and shelf-life performance.
Whether you are developing an early-stage oligonucleotide candidate or preparing for clinical-stage manufacturing, Protheragen provides integrated support for aqueous injection formulation, process development, aseptic manufacturing, filling, analytical testing, and stability evaluation. Contact us to discuss your oligonucleotide drug product requirements and develop a manufacturing strategy tailored to your molecule, formulation, and development stage.
Reference
- DeCollibus DP, et al. "Considerations for the Terminal Sterilization of Oligonucleotide Drug Products" Nucleic Acid Ther. 2023; 33(3):159-177.
